Carl applies his scientific and legal training toward acquiring, protecting and managing patent rights for clients in the biotechnology, chemistry, pharmaceutical and medical device industries.

Carl has particular expertise in developing and prosecuting patent portfolios for FDA-approved or soon-to-be approved drug products, including for products involved or expected to be involved in litigation. He also devises and executes strategies to secure second and third generation patent coverage that extends pharmaceutical product exclusivity (e.g., formulation, dosing regimens and impurity profiles). Examples of FDA-approved drug products on which Carl has developed patent strategies include Krazati®, Beyfortus®, Imjudo®, Saphnelo®, Ibrance®, OxyContin®, Targiniq®, Fasenra™, Epanova®, Sitavig®, Oravig®, Bosulif®, Zetia® and Vytorin®.

Carl has prepared and prosecuted patent applications in the U.S. Patent and Trademark Office and numerous foreign patent offices. His practice also includes pre-litigation case assessments; preparing patentability, validity, infringement and enforcement opinions; and due diligence evaluations. He is experienced in post-grant patent proceedings when product-critical patents are at stake, such as reissues, reexaminations and European oppositions. Carl has also prepared numerous patent term adjustment petitions and patent term extension applications and conducted Orange Book listing investigations. Carl is a frequent speaker and author on developments in patents for life sciences companies. In addition to speaking engagements around the Untied States, he has recently co-authored “Emerging Legal Terrain: IP Risks from AI’s Role in Drug Discovery,” (May 2024) and “FTC Employs New Tactic in Effort Against Drug Makers Alleged to Have Improperly Listed Patents in the FDA’s Orange Book,” (November 2023).